Making Medicare Like Medicaid: High Anxiety For Drug Makers
Executive Summary
While there's no active proposal on the table in Congress for Medicare to adopt Medicaid-like pricing, given the US election year uncertainties and the current increased focus on drug pricing, analysts insisted that although such a scenario represented the worst case, it's the most reasonably realistic situation under which the government could try to rein in spending on prescription medicines.
You may also be interested in...
Analysts: Xtandi March-In Demands 'Noise,' 'Misguided'
A demand by a group of lawmakers for the National Institutes of Health (NIH) to use its "march-in rights" authority as a way to bring down the US price of Medivation Inc.'s and Astellas Pharma Inc.'s prostate cancer drug Xtandi (enzalutamide) is simply "noise" and an action the agency is unlikely to take, analysts said on March 29.
PhRMA Condemns Medicare B Rx Drug Payment Experiment
The Pharmaceutical Researchers and Manufacturers of America (PhRMA) wasted no time in condemning the Obama administration's plans to launch a new experiment testing whether alternative payment designs may lead to reducing Medicare Part B expenditures, while preserving and potentially even enhancing beneficiaries' quality of care.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.